{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:03:58Z","timestamp":1789434238086,"version":"build-2803163510"},"reference-count":194,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03522-3","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:35:50Z","timestamp":1789432550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Smart Surface-Engineered Mesoporous Silica Nanoparticles for Brain Tumor Therapy: Overcoming the Blood\u2013Brain Barrier for Advanced Theranostics"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3152-0233","authenticated-orcid":false,"given":"Rachana","family":"SP","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9685-9749","authenticated-orcid":false,"given":"Rahul","family":"Pokale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8398-4276","authenticated-orcid":false,"given":"Deepanjan","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4777-1042","authenticated-orcid":false,"given":"Gaurisha alias Resha Ramnath","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6350-3912","authenticated-orcid":false,"given":"Sandesh Ramchandra","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3440-2193","authenticated-orcid":false,"given":"Ritu","family":"Kudarha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0642-1928","authenticated-orcid":false,"given":"Srinivas","family":"Mutalik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9852-2653","authenticated-orcid":false,"given":"Namdev","family":"Dhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"3522_CR1","doi-asserted-by":"publisher","first-page":"102802","DOI":"10.1016\/j.jddst.2021.102802","volume":"66","author":"N Mozafari","year":"2021","unstructured":"Mozafari N, Ashrafi H, Azadi A. Targeted drug delivery systems to control neuroinflammation in central nervous system disorders. J Drug Deliv Sci Technol. 2021;66:102802. https:\/\/doi.org\/10.1016\/j.jddst.2021.102802.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3522_CR2","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.semcancer.2019.10.010","volume":"60","author":"TT Lah","year":"2020","unstructured":"Lah TT, Novak M, Breznik B. Brain malignancies: glioblastoma and brain metastases. Semin Cancer Biol. 2020;60:262\u201373. https:\/\/doi.org\/10.1016\/j.semcancer.2019.10.010.","journal-title":"Semin Cancer Biol"},{"key":"3522_CR3","doi-asserted-by":"publisher","first-page":"1441460","DOI":"10.3389\/fonc.2024.1441460","volume":"14","author":"WH Bae","year":"2024","unstructured":"Bae WH, Maraka S, Daher A. Challenges and advances in glioblastoma targeted therapy: the promise of drug repurposing and biomarker exploration. Front Oncol. 2024;14:1441460. https:\/\/doi.org\/10.3389\/fonc.2024.1441460.","journal-title":"Front Oncol"},{"key":"3522_CR4","doi-asserted-by":"publisher","unstructured":"Dighe P. 7 - Biomedical applications of nanocarriers in brain tumor targeting. In: Kumar L, Pathak YY, editors. Nanocarriers for Drug-Targeting Brain Tumors [Internet]. Elsevier; 2022 [cited 2024 July 25]. p. 205\u201333. https:\/\/doi.org\/10.1016\/B978-0-323-90773-6.00011-7","DOI":"10.1016\/B978-0-323-90773-6.00011-7"},{"key":"3522_CR5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/B978-0-323-90773-6.00001-4","volume-title":"Nanocarriers for drug-targeting brain tumors","author":"J Jose","year":"2022","unstructured":"Jose J, Bandiwadekar A, Figreda GG, Crasta CM. 14 - Dendrimers as carriers for active targeting of brain tumors. In: Kumar L, Pathak YY, editors. Nanocarriers for drug-targeting brain tumors. Elsevier; 2022. p. 401\u201330. https:\/\/doi.org\/10.1016\/B978-0-323-90773-6.00001-4."},{"key":"3522_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.addr.2013.09.006","volume":"66","author":"Y Cheng","year":"2014","unstructured":"Cheng Y, Morshed RA, Auffinger B, Tobias AL, Lesniak MS. Multifunctional nanoparticles for brain tumor imaging and therapy. Adv Drug Deliv Rev. 2014;66:42\u201357. https:\/\/doi.org\/10.1016\/j.addr.2013.09.006.","journal-title":"Adv Drug Deliv Rev"},{"key":"3522_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2217\/nnm.12.185","volume":"8","author":"JD Meyers","year":"2013","unstructured":"Meyers JD, Doane T, Burda C, Basilion JP. Nanoparticles for imaging and treating brain cancer. Nanomedicine (Lond). 2013;8:123\u201343. https:\/\/doi.org\/10.2217\/nnm.12.185.","journal-title":"Nanomedicine (Lond)"},{"key":"3522_CR8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41571-019-0177-5","volume":"16","author":"K Aldape","year":"2019","unstructured":"Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, et al. Challenges to curing primary brain tumours. Nat Rev Clin Oncol. 2019;16:509\u201320. https:\/\/doi.org\/10.1038\/s41571-019-0177-5.","journal-title":"Nat Rev Clin Oncol."},{"key":"3522_CR9","doi-asserted-by":"publisher","unstructured":"Cheng Y, Morshed R, Auffinger B, Tobias AL, Lesniak MS. Multifunctional nanoparticles for brain tumor diagnosis and therapy. Adv Drug Deliv Rev. 2014;0:42\u201357. https:\/\/doi.org\/10.1016\/j.addr.2013.09.006","DOI":"10.1016\/j.addr.2013.09.006"},{"key":"3522_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.5599\/admet.2043","volume":"12","author":"M Kulkarni","year":"2023","unstructured":"Kulkarni M, Patel K, Patel A, Patel S, Desai J, Patel M, et al. Nanomaterials as drug delivery agents for overcoming the blood-brain barrier: a comprehensive review. ADMET DMPK. 2023;12:63\u2013105. https:\/\/doi.org\/10.5599\/admet.2043.","journal-title":"ADMET DMPK"},{"key":"3522_CR11","doi-asserted-by":"publisher","first-page":"2408898","DOI":"10.1002\/smll.202408898","volume":"21","author":"S Yousefiasl","year":"2025","unstructured":"Yousefiasl S, Ghovvati M, Alibakhshi A, Azizi M, Samadi P, Kumar A, et al. Smart mesoporous silica nanoparticles in cancer: diagnosis, treatment, immunogenicity, and clinical translation. Small. 2025;21:2408898. https:\/\/doi.org\/10.1002\/smll.202408898.","journal-title":"Small"},{"key":"3522_CR12","doi-asserted-by":"publisher","unstructured":"Kumar L, Pathak YY, editors. Index. Nanocarriers for drug-targeting brain tumors [Internet]. Elsevier; 2022 [cited 2024 July 25]. p. 821\u201334. https:\/\/doi.org\/10.1016\/B978-0-323-90773-6.09993-0","DOI":"10.1016\/B978-0-323-90773-6.09993-0"},{"key":"3522_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/pharmaceutics13020152","volume":"13","author":"ED Mohamed Isa","year":"2021","unstructured":"Mohamed Isa ED, Ahmad H, Abdul Rahman MB, Gill MR. Progress in mesoporous silica nanoparticles as drug delivery agents for cancer treatment. Pharmaceutics. 2021;13:152. https:\/\/doi.org\/10.3390\/pharmaceutics13020152.","journal-title":"Pharmaceutics"},{"key":"3522_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12645-024-00250-w","volume":"15","author":"Y Dutta Gupta","year":"2024","unstructured":"Dutta Gupta Y, Mackeyev Y, Krishnan S, Bhandary S. Mesoporous silica nanotechnology: promising advances in augmenting cancer theranostics. Cancer Nanotechnol. 2024;15:9. https:\/\/doi.org\/10.1186\/s12645-024-00250-w.","journal-title":"Cancer Nanotechnol"},{"key":"3522_CR15","doi-asserted-by":"publisher","first-page":"488","DOI":"10.2174\/157340611796799113","volume":"7","author":"BG Nair","year":"2011","unstructured":"Nair BG, Varghese SH, Nair R, Yoshida Y, Maekawa T, Kumar DS. Nanotechnology platforms; an innovative approach to brain tumor therapy. Med Chem. 2011;7:488\u2013503. https:\/\/doi.org\/10.2174\/157340611796799113.","journal-title":"Med Chem"},{"key":"3522_CR16","doi-asserted-by":"publisher","first-page":"124719","DOI":"10.1016\/j.ijpharm.2024.124719","volume":"665","author":"D Datta","year":"2024","unstructured":"Datta D, Sulthana S, Strauss J, Puri A, Priyanka Bandi S, Singh S. Reconnoitring signaling pathways and exploiting innovative approaches tailoring multifaceted therapies for skin cancer. Int J Pharm. 2024;665:124719. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124719.","journal-title":"Int J Pharm"},{"key":"3522_CR17","doi-asserted-by":"publisher","first-page":"114485","DOI":"10.1016\/j.addr.2022.114485","volume":"189","author":"AC Correia","year":"2022","unstructured":"Correia AC, Monteiro AR, Silva R, Moreira JN, Sousa Lobo JM, Silva AC. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: crossing or circumventing the blood\u2013brain barrier (BBB) to manage neurological disorders. Adv Drug Deliv Rev. 2022;189:114485. https:\/\/doi.org\/10.1016\/j.addr.2022.114485.","journal-title":"Adv Drug Deliv Rev"},{"key":"3522_CR18","doi-asserted-by":"publisher","first-page":"108731","DOI":"10.5306\/wjco.v16.i9.108731","volume":"16","author":"YT Abdel-Maksoud","year":"2025","unstructured":"Abdel-Maksoud YT, Abdelhaseb AH, Abdo AA-E, Kamel AM, Elsebay MT, Attia MS. Responsive mesoporous silica nanocarriers in glioma therapy: a step forward in overcoming biological barriers. World J Clin Oncol. 2025;16:108731. https:\/\/doi.org\/10.5306\/wjco.v16.i9.108731.","journal-title":"World J Clin Oncol"},{"key":"3522_CR19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.wneu.2024.06.006","volume":"189","author":"MH Shah","year":"2024","unstructured":"Shah MH, Awuah WA, Adebusoye FT, Ahluwalia A, Tan JK, Atallah O. Sir William Macewen (1848\u20131924): pioneering the field of neurosurgery with early breakthroughs in tumor resection. World Neurosurg. 2024;189:132\u20137. https:\/\/doi.org\/10.1016\/j.wneu.2024.06.006.","journal-title":"World Neurosurg"},{"key":"3522_CR20","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1002\/cncr.21539","volume":"104","author":"I Chakrabarti","year":"2005","unstructured":"Chakrabarti I, Cockburn M, Cozen W, Wang Y-P, Preston-Martin S. A population-based description of glioblastoma multiforme in Los Angeles County, 1974\u20131999. Cancer. 2005;104:2798\u2013806. https:\/\/doi.org\/10.1002\/cncr.21539.","journal-title":"Cancer"},{"key":"3522_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11060-005-9100-2","volume":"78","author":"B Dobec-Mei\u0107","year":"2006","unstructured":"Dobec-Mei\u0107 B, Pikija S, Cvetko D, Trkulja V, Pazanin L, Kudeli\u0107 N, et al. Intracranial tumors in adult population of the Varazdin County (Croatia) 1996\u20132004: a population-based retrospective incidence study. J Neurooncol. 2006;78:303\u201310. https:\/\/doi.org\/10.1007\/s11060-005-9100-2.","journal-title":"J Neurooncol"},{"key":"3522_CR22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.4103\/2152-7806.90696","volume":"2","author":"M Dobes","year":"2000","unstructured":"Dobes M, Khurana VG, Shadbolt B, Jain S, Smith SF, Smee R, et al. Increasing incidence of glioblastoma multiforme and meningioma, and decreasing incidence of Schwannoma (2000-2008): findings of a multicenter Australian study. Surg Neurol Int. 2000;2:176. https:\/\/doi.org\/10.4103\/2152-7806.90696.","journal-title":"Surg Neurol Int"},{"key":"3522_CR23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ejca.2014.12.014","volume":"51","author":"A Brodbelt","year":"2015","unstructured":"Brodbelt A, Greenberg D, Winters T, Williams M, Vernon S, Collins VP, et al. Glioblastoma in England: 2007\u20132011. Eur J Cancer. 2015;51:533\u201342. https:\/\/doi.org\/10.1016\/j.ejca.2014.12.014.","journal-title":"Eur J Cancer"},{"key":"3522_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.14791\/btrt.2017.5.1.16","volume":"5","author":"Y-S Dho","year":"2017","unstructured":"Dho Y-S, Jung K-W, Ha J, Seo Y, Park C-K, Won Y-J, et al. An updated nationwide epidemiology of primary brain tumors in Republic of Korea, 2013. Brain Tumor Res Treat. 2017;5:16\u201323. https:\/\/doi.org\/10.14791\/btrt.2017.5.1.16.","journal-title":"Brain Tumor Res Treat."},{"key":"3522_CR25","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4103\/ijc.IJC_157_17","volume":"54","author":"M Ghosh","year":"2017","unstructured":"Ghosh M, Shubham S, Mandal K, Trivedi V, Chauhan R, Naseera S. Survival and prognostic factors for glioblastoma multiforme: Retrospective single-institutional study. Indian J Cancer. 2017;54:362\u20137. https:\/\/doi.org\/10.4103\/ijc.IJC_157_17.","journal-title":"Indian J Cancer"},{"key":"3522_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11060-018-03065-z","volume":"142","author":"P Fabbro-Peray","year":"2019","unstructured":"Fabbro-Peray P, Zouaoui S, Darlix A, Fabbro M, Pallud J, Rigau V, et al. Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study. J Neurooncol. 2019;142:91\u2013101. https:\/\/doi.org\/10.1007\/s11060-018-03065-z.","journal-title":"J Neurooncol"},{"key":"3522_CR27","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.3390\/cancers14102412","volume":"14","author":"S Grochans","year":"2022","unstructured":"Grochans S, Cybulska AM, Simi\u0144ska D, Korbecki J, Kojder K, Chlubek D, et al. Epidemiology of glioblastoma multiforme\u2013literature review. Cancers (Basel). 2022;14:2412. https:\/\/doi.org\/10.3390\/cancers14102412.","journal-title":"Cancers (Basel)"},{"key":"3522_CR28","doi-asserted-by":"publisher","first-page":"e8195","DOI":"10.7759\/cureus.8195","volume":"12","author":"N Grech","year":"2020","unstructured":"Grech N, Dalli T, Mizzi S, Meilak L, Calleja N, Zrinzo A. Rising incidence of glioblastoma multiforme in a well-defined population. Cureus. 2020;12:e8195. https:\/\/doi.org\/10.7759\/cureus.8195.","journal-title":"Cureus"},{"key":"3522_CR29","unstructured":"Inc P. Brain Cancer Awareness Month 2025: Data, Advances, and Advocacy - OncoDaily [Internet]. 2025 [cited 2025 Aug 20]. https:\/\/oncodaily.com\/blog\/brain-cancer-292128. Accessed 20 Aug 2025"},{"key":"3522_CR30","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1093\/neuonc\/nox091","volume":"19","author":"R Leece","year":"2017","unstructured":"Leece R, Xu J, Ostrom QT, Chen Y, Kruchko C, Barnholtz-Sloan JS. Global incidence of malignant brain and other central nervous system tumors by histology, 2003\u20132007. Neuro Oncol. 2017;19:1553\u201364. https:\/\/doi.org\/10.1093\/neuonc\/nox091.","journal-title":"Neuro Oncol"},{"key":"3522_CR31","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.7150\/thno.69682","volume":"12","author":"DH Upton","year":"2022","unstructured":"Upton DH, Ung C, George SM, Tsoli M, Kavallaris M, Ziegler DS. Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy. Theranostics. 2022;12:4734\u201352. https:\/\/doi.org\/10.7150\/thno.69682.","journal-title":"Theranostics"},{"key":"3522_CR32","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10545-013-9608-0","volume":"36","author":"NJ Abbott","year":"2013","unstructured":"Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis. 2013;36:437\u201349. https:\/\/doi.org\/10.1007\/s10545-013-9608-0.","journal-title":"J Inherit Metab Dis"},{"key":"3522_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis CD, Ferraro GB, Jain RK. The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20:26\u201341. https:\/\/doi.org\/10.1038\/s41568-019-0205-x.","journal-title":"Nat Rev Cancer"},{"key":"3522_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01260-z","volume":"8","author":"S Li","year":"2023","unstructured":"Li S, Wang C, Chen J, Lan Y, Zhang W, Kang Z, et al. Signaling pathways in brain tumors and therapeutic interventions. Sig Transduct Target Ther. 2023;8:1\u201323. https:\/\/doi.org\/10.1038\/s41392-022-01260-z.","journal-title":"Sig Transduct Target Ther."},{"key":"3522_CR35","doi-asserted-by":"publisher","unstructured":"de Vries NA, Beijnen, Jos H, Boogerd, Willem, and van Tellingen O. Blood\u2013brain barrier and chemotherapeutic treatment of brain tumors. Exp Rev Neurother. 2006;6:1199\u2013209. https:\/\/doi.org\/10.1586\/14737175.6.8.1199","DOI":"10.1586\/14737175.6.8.1199"},{"key":"3522_CR36","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.3390\/cancers16193300","volume":"16","author":"M Duan","year":"2024","unstructured":"Duan M, Cao R, Yang Y, Chen X, Liu L, Ren B, et al. Blood\u2013brain barrier conquest in glioblastoma nanomedicine: strategies, clinical advances, and emerging challenges. Cancers (Basel). 2024;16:3300. https:\/\/doi.org\/10.3390\/cancers16193300.","journal-title":"Cancers (Basel)"},{"key":"3522_CR37","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1158\/1078-0432.CCR-22-1682","volume":"29","author":"CA Von Roemeling","year":"2023","unstructured":"Von Roemeling CA, Doonan BP, Klippel K, Schultz D, Hoang-Minh L, Trivedi V, et al. Oral IRAK-4 inhibitor CA-4948 is blood-brain barrier penetrant and has single-agent activity against CNS lymphoma and melanoma brain metastases. Clin Cancer Res. 2023;29:1751\u201362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1682.","journal-title":"Clin Cancer Res"},{"key":"3522_CR38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2119\/molmed.2010.00062","volume":"17","author":"IV Ulasov","year":"2011","unstructured":"Ulasov IV, Nandi S, Dey M, Sonabend AM, Lesniak MS. Inhibition of sonic hedgehog and notch pathways enhances sensitivity of CD133+ glioma stem cells to temozolomide therapy. Mol Med. 2011;17:103\u201312. https:\/\/doi.org\/10.2119\/molmed.2010.00062.","journal-title":"Mol Med"},{"issue":"2","key":"3522_CR39","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1021\/acs.bioconjchem.4c00537","volume":"36","author":"P An","year":"2025","unstructured":"An P, Tong Y, Mu R, Han L. Wnt-Regulated therapeutics for blood-brain barrier modulation and cancer therapy. Bioconjugate Chemistry. 2025;36(2):136\u201345. https:\/\/doi.org\/10.1021\/acs.bioconjchem.4c00537.","journal-title":"Bioconjugate Chemistry."},{"key":"3522_CR40","doi-asserted-by":"publisher","unstructured":"Sun P, Xiao, Yue, Di, Qianqian, Ma, Wenjing, Ma, Xingyu, Wang, Qingqing, et al. Transferrin receptor-targeted PEG-PLA polymeric micelles for chemotherapy against glioblastoma multiforme. Int J Nanomed. 2020;15:6673\u201388. https:\/\/doi.org\/10.2147\/IJN.S257459","DOI":"10.2147\/IJN.S257459"},{"key":"3522_CR41","doi-asserted-by":"publisher","first-page":"107819","DOI":"10.1016\/j.jddst.2025.107819","volume":"115","author":"M Keerikkadu","year":"2026","unstructured":"Keerikkadu M, Shetty A, Bangera PD, Tippavajhala VK, Rathnanand M. Hybrid transferosomes as multifunctional nanocarriers for enhanced targeted therapy and theranostic drug delivery in complex diseases. J Drug Deliv Sci Technol. 2026;115:107819. https:\/\/doi.org\/10.1016\/j.jddst.2025.107819.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3522_CR42","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1021\/acsnano.3c10674","volume":"18","author":"S Zha","year":"2024","unstructured":"Zha S, Liu H, Li H, Li H, Wong K-L, All AH. Functionalized nanomaterials capable of crossing the blood-brain barrier. ACS Nano. 2024;18:1820\u201345. https:\/\/doi.org\/10.1021\/acsnano.3c10674.","journal-title":"ACS Nano"},{"key":"3522_CR43","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/nrd2368","volume":"6","author":"C Romeo","year":"2007","unstructured":"Romeo C, Vincent B, Stefan L, Maxime C, Mila R, Marie-Pierre D, et al. Modelling of the blood\u2013brain barrier in drug discovery and development. Nat Rev Drug Discov. 2007;6:650\u201361. https:\/\/doi.org\/10.1038\/nrd2368.","journal-title":"Nat Rev Drug Discov."},{"key":"3522_CR44","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2174\/0113816128328722240828184410","volume":"31","author":"U Nayak","year":"2025","unstructured":"Nayak U, Halagali P, Panchal KN, Tippavajhala VK, Mudgal J, Radhakrishnan R, et al. Nanoparticles in CNS therapeutics: pioneering drug delivery advancements. Curr Pharmaceut Des. 2025;31:443\u201360. https:\/\/doi.org\/10.2174\/0113816128328722240828184410.","journal-title":"Curr Pharmaceut Des"},{"key":"3522_CR45","doi-asserted-by":"publisher","unstructured":"Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood\u2013brain barrier: Structure regulation and drug delivery. Abstract\u00a0Sig Transduct Target Ther. 2023;8(1). https:\/\/doi.org\/10.1038\/s41392-023-01481-w.","DOI":"10.1038\/s41392-023-01481-w"},{"key":"3522_CR46","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jconrel.2017.12.015","volume":"270","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Peng Z, Seven ES, Leblanc RM. Crossing the blood-brain barrier with nanoparticles. J Control Release. 2018;270:290\u2013303. https:\/\/doi.org\/10.1016\/j.jconrel.2017.12.015.","journal-title":"J Control Release"},{"key":"3522_CR47","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.3390\/ijms23084153","volume":"23","author":"AM Hersh","year":"2022","unstructured":"Hersh AM, Alomari S, Tyler BM. Crossing the blood-brain barrier: advances in nanoparticle technology for drug delivery in neuro-oncology. Int J Mol Sci. 2022;23:4153. https:\/\/doi.org\/10.3390\/ijms23084153.","journal-title":"Int J Mol Sci"},{"key":"3522_CR48","doi-asserted-by":"publisher","first-page":"6811","DOI":"10.1021\/acsami.5b11730","volume":"8","author":"J Mo","year":"2016","unstructured":"Mo J, He L, Ma B, Chen T. Tailoring particle size of mesoporous silica nanosystem to antagonize glioblastoma and overcome blood\u2013brain barrier. ACS Appl Mater Interfaces. 2016;8:6811\u201325. https:\/\/doi.org\/10.1021\/acsami.5b11730.","journal-title":"ACS Appl Mater Interfaces."},{"key":"3522_CR49","doi-asserted-by":"publisher","unstructured":"Gupta A, P RS, Moorkoth S, Dhas N. Central composite design aided optimization and validation of developed an eco-friendly HPLC method for the quantification of Lenalidomide loaded mesoporous silica nanoparticles. J App Pharm Sci. 2024;15:089\u2013101. https:\/\/doi.org\/10.7324\/JAPS.2024.189998.","DOI":"10.7324\/JAPS.2024.189998"},{"key":"3522_CR50","doi-asserted-by":"publisher","first-page":"29247","DOI":"10.1038\/srep29247","volume":"6","author":"MA Shevtsov","year":"2016","unstructured":"Shevtsov MA, Parr MA, Ryzhov VA, Zemtsova EG, Arbenin AY, Ponomareva AN, et al. Zero-valent Fe confined mesoporous silica nanocarriers (Fe(0) @ MCM-41) for targeting experimental orthotopic glioma in rats. Sci Rep. 2016;6:29247. https:\/\/doi.org\/10.1038\/srep29247.","journal-title":"Sci Rep."},{"key":"3522_CR51","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00210-024-03469-x","volume":"398","author":"AP Mishra","year":"2025","unstructured":"Mishra AP, Kumar R, Harilal S, Nigam M, Datta D, Singh S, et al. Demystifying the management of cancer through smart nano-biomedicine via regulation of reactive oxygen species. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. 2025;398:497\u2013532. https:\/\/doi.org\/10.1007\/s00210-024-03469-x.","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"3522_CR52","doi-asserted-by":"publisher","first-page":"1900195","DOI":"10.1002\/ppsc.201900195","volume":"36","author":"S Mendiratta","year":"2019","unstructured":"Mendiratta S, Hussein M, Nasser HA, Ali AAA. Multidisciplinary role of mesoporous silica nanoparticles in brain regeneration and cancers: from crossing the blood-brain barrier to treatment. Part Part Syst Charact. 2019;36:1900195. https:\/\/doi.org\/10.1002\/ppsc.201900195.","journal-title":"Part Part Syst Charact"},{"key":"3522_CR53","doi-asserted-by":"publisher","first-page":"13152","DOI":"10.1021\/acs.jmedchem.1c00910","volume":"64","author":"B Xiong","year":"2021","unstructured":"Xiong B, Wang Y, Chen Y, Xing S, Liao Q, Chen Y, et al. Strategies for structural modification of small molecules to improve blood-brain barrier penetration: a recent perspective. J Med Chem. 2021;64:13152\u201373. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00910.","journal-title":"J Med Chem"},{"key":"3522_CR54","doi-asserted-by":"publisher","first-page":"602236","DOI":"10.3389\/fmedt.2020.602236","volume":"2","author":"WM Pardridge","year":"2020","unstructured":"Pardridge WM. Brain delivery of nanomedicines: Trojan Horse liposomes for plasmid DNA gene therapy of the brain. Front Med Technol. 2020;2:602236. https:\/\/doi.org\/10.3389\/fmedt.2020.602236.","journal-title":"Front Med Technol"},{"key":"3522_CR55","doi-asserted-by":"publisher","unstructured":"Namdar N, Fasaei BN, Shariati P, Joghataei SM, Arpanaei A. Lysozyme and vancomycin co-loaded on mesoporous silica nanoparticles; a \u201cTrojan Horse\u201d with synergistic antimicrobial effects [Internet]. Research Square; 2024 [cited 2025 Jan 31]. https:\/\/doi.org\/10.21203\/rs.3.rs-4663577\/v1","DOI":"10.21203\/rs.3.rs-4663577\/v1"},{"key":"3522_CR56","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.colsurfb.2014.12.045","volume":"126","author":"U Agrawal","year":"2015","unstructured":"Agrawal U, Chashoo G, Sharma PR, Kumar A, Saxena AK, Vyas SP. Tailored polymer\u2013lipid hybrid nanoparticles for the delivery of drug conjugate: dual strategy for brain targeting. Colloids Surf B. 2015;126:414\u201325. https:\/\/doi.org\/10.1016\/j.colsurfb.2014.12.045.","journal-title":"Colloids Surf B"},{"key":"3522_CR57","doi-asserted-by":"publisher","first-page":"11910","DOI":"10.1039\/C9NR02876E","volume":"11","author":"O Turan","year":"2019","unstructured":"Turan O, Bielecki P, Perera V, Lorkowski M, Covarrubias G, Tong K, et al. Delivery of drugs into brain tumors using multicomponent silica nanoparticles. Nanoscale. 2019;11:11910\u201321. https:\/\/doi.org\/10.1039\/C9NR02876E.","journal-title":"Nanoscale"},{"key":"3522_CR58","doi-asserted-by":"publisher","first-page":"e0160705","DOI":"10.1371\/journal.pone.0160705","volume":"11","author":"H Baghirov","year":"2016","unstructured":"Baghirov H, Karaman D, Viitala T, Duchanoy A, Lou Y-R, Mamaeva V, et al. Feasibility study of the permeability and uptake of mesoporous silica nanoparticles across the blood-brain barrier. PLoS ONE. 2016;11:e0160705. https:\/\/doi.org\/10.1371\/journal.pone.0160705.","journal-title":"PLoS ONE"},{"key":"3522_CR59","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3390\/pharmaceutics13071067","volume":"13","author":"E Rastegari","year":"2021","unstructured":"Rastegari E, Hsiao Y-J, Lai W-Y, Lai Y-H, Yang T-C, Chen S-J, et al. An update on mesoporous silica nanoparticle applications in nanomedicine. Pharmaceutics. 2021;13:1067. https:\/\/doi.org\/10.3390\/pharmaceutics13071067.","journal-title":"Pharmaceutics."},{"key":"3522_CR60","doi-asserted-by":"publisher","first-page":"20661","DOI":"10.1038\/s41598-022-25095-4","volume":"12","author":"OA Saputra","year":"2022","unstructured":"Saputra OA, Lestari WA, Kurniansyah V, Lestari WW, Sugiura T, Mukti RR, et al. Organically surface engineered mesoporous silica nanoparticles control the release of quercetin by pH stimuli. Sci Rep. 2022;12:20661. https:\/\/doi.org\/10.1038\/s41598-022-25095-4.","journal-title":"Sci Rep."},{"key":"3522_CR61","doi-asserted-by":"publisher","first-page":"931584","DOI":"10.3389\/fchem.2022.931584","volume":"10","author":"Y-P Chen","year":"2022","unstructured":"Chen Y-P, Chou C-M, Chang T-Y, Ting H, Demb\u00e9l\u00e9 J, Chu Y-T, et al. Bridging size and charge effects of mesoporous silica nanoparticles for crossing the blood-brain barrier. Front Chem. 2022;10:931584. https:\/\/doi.org\/10.3389\/fchem.2022.931584.","journal-title":"Front Chem"},{"key":"3522_CR62","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3390\/pharmaceutics13040570","volume":"13","author":"AN Frickenstein","year":"2021","unstructured":"Frickenstein AN, Hagood JM, Britten CN, Abbott BS, McNally MW, Vopat CA, et al. Mesoporous silica nanoparticles: properties and strategies for enhancing clinical effect. Pharmaceutics. 2021;13:570. https:\/\/doi.org\/10.3390\/pharmaceutics13040570.","journal-title":"Pharmaceutics"},{"key":"3522_CR63","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/17425247.2019.1598375","volume":"16","author":"RR Castillo","year":"2019","unstructured":"Castillo RR, Lozano D, Gonz\u00e1lez B, Manzano M, Izquierdo-Barba I, Vallet-Reg\u00ed M. Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: an update. Expert Opin Drug Deliv. 2019;16:415\u201339. https:\/\/doi.org\/10.1080\/17425247.2019.1598375.","journal-title":"Expert Opin Drug Deliv"},{"key":"3522_CR64","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3390\/pharmaceutics14051113","volume":"14","author":"TA Seidu","year":"2022","unstructured":"Seidu TA, Kutoka PT, Asante DO, Farooq MA, Alolga RN, Bo W. Functionalization of nanoparticulate drug delivery systems and its influence in cancer therapy. Pharmaceutics. 2022;14:1113. https:\/\/doi.org\/10.3390\/pharmaceutics14051113.","journal-title":"Pharmaceutics."},{"key":"3522_CR65","doi-asserted-by":"publisher","unstructured":"Saha A, Mishra P, Biswas G, Bhakta S. Greening the pathways: a comprehensive review of sustainable synthesis strategies for silica nanoparticles and their diverse applications. RSC Adv. 14:11197\u2013216. https:\/\/doi.org\/10.1039\/d4ra01047g","DOI":"10.1039\/d4ra01047g"},{"key":"3522_CR66","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1021\/ar3000986","volume":"46","author":"D Tarn","year":"2013","unstructured":"Tarn D, Ashley CE, Xue M, Carnes EC, Zink JI, Brinker CJ. Mesoporous silica nanoparticle nanocarriers \u2013 biofunctionality and biocompatibility. Acc Chem Res. 2013;46:792\u2013801. https:\/\/doi.org\/10.1021\/ar3000986.","journal-title":"Acc Chem Res"},{"key":"3522_CR67","doi-asserted-by":"publisher","first-page":"17496","DOI":"10.1021\/acsomega.8b02784","volume":"3","author":"C von Baeckmann","year":"2018","unstructured":"von Baeckmann C, Guillet-Nicolas R, Renfer D, K\u00e4hlig H, Kleitz F. A toolbox for the synthesis of multifunctionalized mesoporous silica nanoparticles for biomedical applications. ACS Omega. 2018;3:17496\u2013510. https:\/\/doi.org\/10.1021\/acsomega.8b02784.","journal-title":"ACS Omega"},{"key":"3522_CR68","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.surfrep.2014.07.001","volume":"69","author":"A Liberman","year":"2014","unstructured":"Liberman A, Mendez N, Trogler WC, Kummel AC. Synthesis and surface functionalization of silica nanoparticles for nanomedicine. Surf Sci Rep. 2014;69:132\u201358. https:\/\/doi.org\/10.1016\/j.surfrep.2014.07.001.","journal-title":"Surf Sci Rep"},{"key":"3522_CR69","doi-asserted-by":"publisher","unstructured":"Fatima R, Katiyar P, Kushwaha K. Recent advances in mesoporous silica nanoparticle: synthesis, drug loading, release mechanisms, and diverse applications. Front Nanotechnol [Internet]. Frontiers; 2025 [cited 2026 June 29];7. https:\/\/doi.org\/10.3389\/fnano.2025.1564188","DOI":"10.3389\/fnano.2025.1564188"},{"key":"3522_CR70","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/coatings13010086","volume":"13","author":"L Wang","year":"2023","unstructured":"Wang L, Ni T, Wei S. Thymol-functionalized silica nanomaterials prepared by post-grafting method: preparation, characterization, bactericidal activity and mechanism research. Coatings. 2023;13:86. https:\/\/doi.org\/10.3390\/coatings13010086.","journal-title":"Coatings."},{"key":"3522_CR71","doi-asserted-by":"publisher","first-page":"14328","DOI":"10.1039\/C4RA00781F","volume":"4","author":"SK Natarajan","year":"2014","unstructured":"Natarajan SK, Selvaraj S. Mesoporous silica nanoparticles: importance of surface modifications and its role in drug delivery. RSC Adv. 2014;4:14328\u201334. https:\/\/doi.org\/10.1039\/C4RA00781F.","journal-title":"RSC Adv."},{"key":"3522_CR72","doi-asserted-by":"publisher","first-page":"9176257","DOI":"10.1155\/2020\/9176257","volume":"2020","author":"AM Alswieleh","year":"2020","unstructured":"Alswieleh AM. Modification of mesoporous silica surface by immobilization of functional groups for controlled drug release. J Chem. 2020;2020:9176257. https:\/\/doi.org\/10.1155\/2020\/9176257.","journal-title":"J Chem"},{"key":"3522_CR73","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/open.202100227","volume":"10","author":"BM Estev\u00e3o","year":"2021","unstructured":"Estev\u00e3o BM, Miletto I, Hioka N, Marchese L, Gianotti E. Mesoporous silica nanoparticles functionalized with amino groups for biomedical applications. ChemistryOpen. 2021;10:1251\u20139. https:\/\/doi.org\/10.1002\/open.202100227.","journal-title":"ChemistryOpen"},{"key":"3522_CR74","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1021\/am508219g","volume":"7","author":"N Hao","year":"2015","unstructured":"Hao N, Jayawardana KW, Chen X, De Zoysa T, Yan M. One-step synthesis of amine-functionalized hollow mesoporous silica nanoparticles as efficient antibacterial and anticancer materials. ACS Appl Mater Interfaces. 2015;7:1040\u20135. https:\/\/doi.org\/10.1021\/am508219g.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3522_CR75","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10971-016-4163-4","volume":"80","author":"WA Talavera-Pech","year":"2016","unstructured":"Talavera-Pech WA, Esparza-Ruiz A, Quintana-Owen P, Vilchis-Nestor AR, Carrera-Figueiras C, \u00c1vila-Ortega A. Effects of different amounts of APTES on physicochemical and structural properties of amino-functionalized MCM-41-MSNs. J Sol-Gel Sci Technol. 2016;80:697\u2013708. https:\/\/doi.org\/10.1007\/s10971-016-4163-4.","journal-title":"J Sol-Gel Sci Technol"},{"key":"3522_CR76","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1039\/c9na00772e","volume":"2","author":"PJ Miller","year":"2020","unstructured":"Miller PJ, Shantz DF. Covalently functionalized uniform amino-silica nanoparticles. Synthesis and validation of amine group accessibility and stability. Nanoscale Adv. 2020;2:860\u20138. https:\/\/doi.org\/10.1039\/c9na00772e.","journal-title":"Nanoscale Adv"},{"key":"3522_CR77","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1177\/0885328217724638","volume":"32","author":"Y He","year":"2017","unstructured":"He Y, Luo L, Liang S, Long M, Xu H. Amino-functionalized mesoporous silica nanoparticles as efficient carriers for anticancer drug delivery. J Biomater Appl. 2017;32:524\u201332. https:\/\/doi.org\/10.1177\/0885328217724638.","journal-title":"J Biomater Appl"},{"key":"3522_CR78","doi-asserted-by":"publisher","first-page":"10275","DOI":"10.1021\/acs.inorgchem.0c01436","volume":"59","author":"M Mart\u00ednez-Carmona","year":"2020","unstructured":"Mart\u00ednez-Carmona M, Ho QP, Morand J, Garc\u00eda A, Ortega E, Erthal LCS, et al. Amino-functionalized mesoporous silica nanoparticle-encapsulated octahedral organoruthenium complex as an efficient platform for combatting cancer. Inorg Chem. 2020;59:10275\u201384. https:\/\/doi.org\/10.1021\/acs.inorgchem.0c01436.","journal-title":"Inorg Chem"},{"key":"3522_CR79","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3390\/polym16081105","volume":"16","author":"S Kovtareva","year":"2024","unstructured":"Kovtareva S, Kusepova L, Tazhkenova G, Mashan T, Bazarbaeva K, Kopishev E. Surface modification of mesoporous silica nanoparticles for application in targeted delivery systems of antitumour drugs. Polymers. 2024;16:1105. https:\/\/doi.org\/10.3390\/polym16081105.","journal-title":"Polymers."},{"key":"3522_CR80","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.colsurfb.2016.02.009","volume":"141","author":"J Li","year":"2016","unstructured":"Li J, Du X, Zheng N, Xu L, Xu J, Li S. Contribution of carboxyl modified chiral mesoporous silica nanoparticles in delivering doxorubicin hydrochloride in vitro: pH-response controlled release, enhanced drug cellular uptake and cytotoxicity. Colloids Surf, B. 2016;141:374\u201381. https:\/\/doi.org\/10.1016\/j.colsurfb.2016.02.009.","journal-title":"Colloids Surf, B"},{"key":"3522_CR81","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/molecules23010047","volume":"23","author":"M Vallet-Reg\u00ed","year":"2017","unstructured":"Vallet-Reg\u00ed M, Colilla M, Izquierdo-Barba I, Manzano M. Mesoporous silica nanoparticles for drug delivery: current insights. Molecules. 2017;23:47. https:\/\/doi.org\/10.3390\/molecules23010047.","journal-title":"Molecules"},{"key":"3522_CR82","doi-asserted-by":"publisher","unstructured":"Zhang Y, Xu J. Mesoporous silica nanoparticle-based intelligent drug delivery system for bienzyme-responsive tumour targeting and controlled release. Royal Society Open Science [Internet]. The Royal Society Publishing; 2018 [cited 2025 Mar 17]; https:\/\/doi.org\/10.1098\/rsos.170986","DOI":"10.1098\/rsos.170986"},{"key":"3522_CR83","doi-asserted-by":"publisher","first-page":"20220867","DOI":"10.1515\/biol-2022-0867","volume":"19","author":"W Zhang","year":"2024","unstructured":"Zhang W, Liu H, Qiu X, Zuo F, Wang B. Mesoporous silica nanoparticles as a drug delivery mechanism. Open Life Sci. 2024;19:20220867. https:\/\/doi.org\/10.1515\/biol-2022-0867.","journal-title":"Open Life Sci"},{"key":"3522_CR84","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.actbio.2021.07.023","volume":"134","author":"K Gou","year":"2021","unstructured":"Gou K, Wang Y, Guo X, Wang Y, Bian Y, Zhao H, et al. Carboxyl-functionalized mesoporous silica nanoparticles for the controlled delivery of poorly water-soluble non-steroidal anti-inflammatory drugs. Acta Biomater. 2021;134:576\u201392. https:\/\/doi.org\/10.1016\/j.actbio.2021.07.023.","journal-title":"Acta Biomater"},{"key":"3522_CR85","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3390\/pharmaceutics14020469","volume":"14","author":"A Badea","year":"2022","unstructured":"Badea A, Balas M, Prodana M, Piciu F, Ionita D, Dinischiotu A. Carboxyl-functionalized carbon nanotubes loaded with cisplatin promote the inhibition of PI3K\/Akt pathway and suppress the migration of breast cancer cells. Pharmaceutics. 2022;14:469. https:\/\/doi.org\/10.3390\/pharmaceutics14020469.","journal-title":"Pharmaceutics"},{"key":"3522_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biomaterials.2017.07.030","volume":"143","author":"R Zhao","year":"2017","unstructured":"Zhao R, Li T, Zheng G, Jiang K, Fan L, Shao J. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex. Biomaterials. 2017;143:1\u201316. https:\/\/doi.org\/10.1016\/j.biomaterials.2017.07.030.","journal-title":"Biomaterials"},{"key":"3522_CR87","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1021\/acsabm.8b00830","volume":"2","author":"L Cui","year":"2019","unstructured":"Cui L, Liu W, Liu H, Qin Q, Wu S, He S, et al. pH-triggered charge-reversal mesoporous silica nanoparticles stabilized by chitosan oligosaccharide\/carboxymethyl chitosan hybrids for effective intracellular delivery of doxorubicin. ACS Appl Bio Mater. 2019;2:1907\u201319. https:\/\/doi.org\/10.1021\/acsabm.8b00830.","journal-title":"ACS Appl Bio Mater."},{"key":"3522_CR88","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.msec.2018.09.043","volume":"94","author":"D Saikia","year":"2019","unstructured":"Saikia D, Deka JR, Wu C-E, Yang Y-C, Kao H-M. pH responsive selective protein adsorption by carboxylic acid functionalized large pore mesoporous silica nanoparticles SBA-1. Mater Sci Eng, C. 2019;94:344\u201356. https:\/\/doi.org\/10.1016\/j.msec.2018.09.043.","journal-title":"Mater Sci Eng, C"},{"key":"3522_CR89","doi-asserted-by":"publisher","first-page":"128957","DOI":"10.1016\/j.cej.2021.128957","volume":"415","author":"A Sun","year":"2021","unstructured":"Sun A, Qian D, Wang Z, Xu Y, Ye H, Fang C-J, et al. Protective effect of lipoic acid modification on brain dysfunctions of mice induced by mesoporous silica nanoparticles. Chem Eng J. 2021;415:128957. https:\/\/doi.org\/10.1016\/j.cej.2021.128957.","journal-title":"Chem Eng J"},{"key":"3522_CR90","doi-asserted-by":"publisher","first-page":"e2204643","DOI":"10.1002\/advs.202204643","volume":"10","author":"C-C Chen","year":"2023","unstructured":"Chen C-C, Fa Y-C, Kuo Y-Y, Liu Y-C, Lin C-Y, Wang X-H, et al. Thiolated mesoporous silica nanoparticles as an immunoadjuvant to enhance efficacy of intravesical chemotherapy for bladder cancer. Adv Sci (Weinh). 2023;10:e2204643. https:\/\/doi.org\/10.1002\/advs.202204643.","journal-title":"Adv Sci (Weinh)"},{"key":"3522_CR91","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1021\/acsbiomaterials.3c00479","volume":"9","author":"N Rasool","year":"2023","unstructured":"Rasool N, Negi D, Singh Y. Thiol-functionalized, antioxidant, and osteogenic mesoporous silica nanoparticles for osteoporosis. ACS Biomater Sci Eng. 2023;9:3535\u201345. https:\/\/doi.org\/10.1021\/acsbiomaterials.3c00479.","journal-title":"ACS Biomater Sci Eng"},{"key":"3522_CR92","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1021\/jacsau.1c00128","volume":"1","author":"Q Laurent","year":"2021","unstructured":"Laurent Q, Martinent R, Lim B, Pham A-T, Kato T, L\u00f3pez-Andarias J, et al. Thiol-mediated uptake. JACS Au. 2021;1:710\u201328. https:\/\/doi.org\/10.1021\/jacsau.1c00128.","journal-title":"JACS Au"},{"key":"3522_CR93","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1021\/acs.bioconjchem.2c00305","volume":"33","author":"LE Waggoner","year":"2022","unstructured":"Waggoner LE, Kang J, Zuidema JM, Vijayakumar S, Hurtado AA, Sailor MJ, et al. Porous silicon nanoparticles targeted to the extracellular matrix for therapeutic protein delivery in traumatic brain injury. Bioconjugate Chem. 2022;33:1685\u201397. https:\/\/doi.org\/10.1021\/acs.bioconjchem.2c00305.","journal-title":"Bioconjugate Chem"},{"key":"3522_CR94","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1039\/C5RA17517H","volume":"6","author":"M Zhou","year":"2016","unstructured":"Zhou M, Xie L, Fang C-J, Yang H, Wang Y-J, Zhen X-Y, et al. Implications for blood-brain-barrier permeability, in vitro oxidative stress and neurotoxicity potential induced by mesoporous silica nanoparticles: effects of surface modification. RSC Advances Royal Society of Chemistry. 2016;6:2800\u20139. https:\/\/doi.org\/10.1039\/C5RA17517H.","journal-title":"RSC Advances Royal Society of Chemistry"},{"key":"3522_CR95","doi-asserted-by":"publisher","first-page":"6772","DOI":"10.1021\/acsami.6b14049","volume":"9","author":"PA Ellison","year":"2017","unstructured":"Ellison PA, Chen F, Goel S, Barnhart TE, Nickles RJ, DeJesus OT, et al. Intrinsic and stable conjugation of thiolated mesoporous silica nanoparticles with radioarsenic. ACS Appl Mater Interfaces. 2017;9:6772\u201381. https:\/\/doi.org\/10.1021\/acsami.6b14049.","journal-title":"ACS Appl Mater Interfaces."},{"key":"3522_CR96","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1080\/10717544.2022.2089296","volume":"29","author":"R Bajracharya","year":"2022","unstructured":"Bajracharya R, Song JG, Patil BR, Lee SH, Noh H-M, Kim D-H, et al. Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems. Drug Delivery Taylor & Francis. 2022;29:1959\u201370. https:\/\/doi.org\/10.1080\/10717544.2022.2089296.","journal-title":"Drug Delivery Taylor & Francis"},{"key":"3522_CR97","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.2147\/IJN.S75098","volume":"10","author":"Y Liu","year":"2015","unstructured":"Liu Y, Chen Q, Xu M, Guan G, Hu W, Liang Y, et al. Single peptide ligand-functionalized uniform hollow mesoporous silica nanoparticles achieving dual-targeting drug delivery to tumor cells and angiogenic blood vessel cells. Int J Nanomed. 2015;10:1855\u201367. https:\/\/doi.org\/10.2147\/IJN.S75098.","journal-title":"Int J Nanomed."},{"key":"3522_CR98","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/cancers12010187","volume":"12","author":"K OvejeroParedes","year":"2020","unstructured":"OvejeroParedes K, D\u00edaz-Garc\u00eda D, Garc\u00eda-Almod\u00f3var V, Lozano Chamizo L, Marciello M, D\u00edaz-S\u00e1nchez M, et al. Multifunctional silica-based nanoparticles with controlled release of organotin metallodrug for targeted theranosis of breast cancer. Cancers. 2020;12:187. https:\/\/doi.org\/10.3390\/cancers12010187.","journal-title":"Cancers."},{"key":"3522_CR99","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3390\/nano12040608","volume":"12","author":"MA Khan","year":"2022","unstructured":"Khan MA, Ghanim RW, Kiser MR, Moradipour M, Rogers DT, Littleton JM, et al. Strategy for conjugating oligopeptides to mesoporous silica nanoparticles using diazirine-based heterobifunctional linkers. Nanomaterials (Basel). 2022;12:608. https:\/\/doi.org\/10.3390\/nano12040608.","journal-title":"Nanomaterials (Basel)"},{"key":"3522_CR100","doi-asserted-by":"publisher","first-page":"5737","DOI":"10.1039\/b905158a","volume":"19","author":"CP Tsai","year":"2009","unstructured":"Tsai CP, Chen CY, Hung Y, Chang FH, Mou CY. Monoclonal antibody-functionalized mesoporous silica nanoparticles (MSN) for selective targeting breast cancer cells. J Mater Chem. 2009;19:5737\u201343. https:\/\/doi.org\/10.1039\/b905158a.","journal-title":"J Mater Chem"},{"key":"3522_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Sig Transduct Target Ther. 2022;7:1\u201325. https:\/\/doi.org\/10.1038\/s41392-022-00947-7.","journal-title":"Sig Transduct Target Ther."},{"key":"3522_CR102","doi-asserted-by":"publisher","first-page":"21722","DOI":"10.1021\/acsami.4c04289","volume":"16","author":"T-I Hsu","year":"2024","unstructured":"Hsu T-I, Chen Y-P, Zhang R-L, Chen Z-A, Wu C-H, Chang W-C, et al. Overcoming the blood\u2013brain tumor barrier with docetaxel-loaded mesoporous silica nanoparticles for treatment of temozolomide-resistant glioblastoma. ACS Appl Mater Interfaces. 2024;16:21722\u201335. https:\/\/doi.org\/10.1021\/acsami.4c04289.","journal-title":"ACS Appl Mater Interfaces."},{"key":"3522_CR103","doi-asserted-by":"publisher","first-page":"7721","DOI":"10.1039\/C7TB01385J","volume":"5","author":"M Bouchoucha","year":"2017","unstructured":"Bouchoucha M, B\u00e9liveau \u00c9, Kleitz F, Calon F, Fortin M-A. Antibody-conjugated mesoporous silica nanoparticles for brain microvessel endothelial cell targeting. J Mater Chem B. 2017;5:7721\u201335. https:\/\/doi.org\/10.1039\/C7TB01385J.","journal-title":"J Mater Chem B."},{"key":"3522_CR104","doi-asserted-by":"publisher","first-page":"7721","DOI":"10.1039\/C7TB01385J","volume":"5","author":"M Bouchoucha","year":"2017","unstructured":"Bouchoucha M, B\u00e9liveau \u00c9, Kleitz F, Calon F, Fortin M-A. Antibody-conjugated mesoporous silica nanoparticles for brain microvessel endothelial cell targeting. J Mater Chem B Royal Soc Chem. 2017;5:7721\u201335. https:\/\/doi.org\/10.1039\/C7TB01385J.","journal-title":"J Mater Chem B Royal Soc Chem."},{"key":"3522_CR105","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-023-00756-z","volume":"20","author":"MJ Mair","year":"2023","unstructured":"Mair MJ, Bartsch R, Le Rhun E, Berghoff AS, Brastianos PK, Cortes J, et al. Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours. Nat Rev Clin Oncol. 2023;20:372\u201389. https:\/\/doi.org\/10.1038\/s41571-023-00756-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"3522_CR106","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1021\/acsami.6b12647","volume":"9","author":"Y-J Cheng","year":"2017","unstructured":"Cheng Y-J, Zhang A-Q, Hu J-J, He F, Zeng X, Zhang X-Z. Multifunctional peptide-amphiphile end-capped mesoporous silica nanoparticles for tumor targeting drug delivery. ACS Appl Mater Interfaces. 2017;9:2093\u2013103. https:\/\/doi.org\/10.1021\/acsami.6b12647.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3522_CR107","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.bbrc.2020.10.076","volume":"534","author":"J Zhu","year":"2021","unstructured":"Zhu J, Zhang Y, Chen X, Zhang Y, Zhang K, Zheng H, et al. Angiopep-2 modified lipid-coated mesoporous silica nanoparticles for glioma targeting therapy overcoming BBB. Biochem Biophys Res Commun. 2021;534:902\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2020.10.076.","journal-title":"Biochem Biophys Res Commun"},{"key":"3522_CR108","doi-asserted-by":"publisher","unstructured":"Sharma R, Borah SJ, Bhawna, Kumar S, Gupta A, Singh P, et al. Functionalized peptide-based nanoparticles for targeted cancer nanotherapeutics: a state-of-the-art review. ACS Omega. 2022;7:36092\u2013107. https:\/\/doi.org\/10.1021\/acsomega.2c03974","DOI":"10.1021\/acsomega.2c03974"},{"key":"3522_CR109","doi-asserted-by":"publisher","first-page":"12716","DOI":"10.1021\/acsnano.3c08993","volume":"18","author":"Z-A Chen","year":"2024","unstructured":"Chen Z-A, Wu C-H, Wu S-H, Huang C-Y, Mou C-Y, Wei K-C, et al. Receptor ligand-free mesoporous silica nanoparticles: a streamlined strategy for targeted drug delivery across the blood-brain barrier. ACS Nano Am Chem Soc. 2024;18:12716\u201336. https:\/\/doi.org\/10.1021\/acsnano.3c08993.","journal-title":"ACS Nano Am Chem Soc"},{"key":"3522_CR110","doi-asserted-by":"publisher","first-page":"14608","DOI":"10.1039\/C2JM32398B","volume":"22","author":"Y Wang","year":"2012","unstructured":"Wang Y, Shi W, Song W, Wang L, Liu X, Chen J, et al. Tumor cell targeted delivery by specific peptide-modified mesoporous silica nanoparticles. J Mater Chem. 2012;22:14608\u201316. https:\/\/doi.org\/10.1039\/C2JM32398B.","journal-title":"J Mater Chem."},{"key":"3522_CR111","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1002\/smll.201600325","volume":"12","author":"J Hu","year":"2016","unstructured":"Hu J, Xiao D, Zhang X. Advances in peptide functionalization on mesoporous silica nanoparticles for controlled drug release. Small. 2016;12:3344\u201359. https:\/\/doi.org\/10.1002\/smll.201600325.","journal-title":"Small"},{"key":"3522_CR112","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1089\/ten.tea.2014.0297","volume":"21","author":"KA Black","year":"2015","unstructured":"Black KA, Lin BF, Wonder EA, Desai SS, Chung EJ, Ulery BD, et al. Biocompatibility and characterization of a peptide amphiphile hydrogel for applications in peripheral nerve regeneration. Tissue Eng Part A. 2015;21:1333\u201342. https:\/\/doi.org\/10.1089\/ten.tea.2014.0297.","journal-title":"Tissue Eng Part A"},{"key":"3522_CR113","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1039\/c4tb00037d","volume":"2","author":"M Sardan","year":"2014","unstructured":"Sardan M, Yildirim A, Mumcuoglu D, Tekinay AB, Guler MO. Noncovalent functionalization of mesoporous silica nanoparticles with amphiphilic peptides. J Mater Chem B. 2014;2:2168\u201374. https:\/\/doi.org\/10.1039\/c4tb00037d.","journal-title":"J Mater Chem B"},{"key":"3522_CR114","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/cyto.a.22715","volume":"87","author":"M Dela\u010d","year":"2015","unstructured":"Dela\u010d M, Motaln H, Ulrich H, Lah TT. Aptamer for imaging and therapeutic targeting of brain tumor glioblastoma. Cytometry A. 2015;87:806\u201316. https:\/\/doi.org\/10.1002\/cyto.a.22715.","journal-title":"Cytometry A"},{"key":"3522_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42004-024-01255-7","volume":"7","author":"N Soxpollard","year":"2024","unstructured":"Soxpollard N, Strauss S, Jungmann R, MacPherson IS. Selection of antibody-binding covalent aptamers. Commun Chem Nature Publishing Group. 2024;7:1\u201311. https:\/\/doi.org\/10.1038\/s42004-024-01255-7.","journal-title":"Commun Chem Nature Publishing Group"},{"key":"3522_CR116","doi-asserted-by":"publisher","first-page":"15899","DOI":"10.1002\/anie.202101174","volume":"60","author":"Y Tivon","year":"2021","unstructured":"Tivon Y, Falcone G, Deiters A. Protein labeling and crosslinking by covalent aptamers. Angew Chem Int Ed Engl. 2021;60:15899\u2013904. https:\/\/doi.org\/10.1002\/anie.202101174.","journal-title":"Angew Chem Int Ed Engl"},{"key":"3522_CR117","doi-asserted-by":"publisher","unstructured":"Chen Z, Luo H, Gubu A, Yu S, Zhang H, Dai H, et al. Chemically modified aptamers for improving binding affinity to the target proteins via enhanced non-covalent bonding. Front Cell Dev Biol [Internet]. Frontiers; 2023 [cited 2025 Mar 11];11. https:\/\/doi.org\/10.3389\/fcell.2023.1091809","DOI":"10.3389\/fcell.2023.1091809"},{"key":"3522_CR118","doi-asserted-by":"publisher","first-page":"115759","DOI":"10.1016\/j.trac.2019.115759","volume":"123","author":"S Vandghanooni","year":"2020","unstructured":"Vandghanooni S, Barar J, Eskandani M, Omidi Y. Aptamer-conjugated mesoporous silica nanoparticles for simultaneous imaging and therapy of cancer. TrAC Trends Anal Chem. 2020;123:115759. https:\/\/doi.org\/10.1016\/j.trac.2019.115759.","journal-title":"TrAC Trends Anal Chem"},{"key":"3522_CR119","unstructured":"Hennig M. Aptamer-modified chitosan-capped Mesoporous silica nanoparticles for co-delivery of cytarabine and daunorubicin in Leukemia [Internet]. Pharma Excipients. 2023 [cited 2025 Jan 6]. https:\/\/www.pharmaexcipients.com\/news\/cytarabine-daunorubicin-leukemia\/. Accessed 6 Jan 2025"},{"key":"3522_CR120","doi-asserted-by":"publisher","first-page":"122479","DOI":"10.1016\/j.biomaterials.2024.122479","volume":"306","author":"H Fei","year":"2024","unstructured":"Fei H, Jin Y, Jiang N, Zhou Y, Wei N, Liu Y, et al. Gint4.T-siHDGF chimera-capped mesoporous silica nanoparticles encapsulating temozolomide for synergistic glioblastoma therapy. Biomaterials. 2024;306:122479. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122479.","journal-title":"Biomaterials."},{"key":"3522_CR121","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/biomedicines12010187","volume":"12","author":"D Park","year":"2024","unstructured":"Park D, Lee SJ, Park J-W. Aptamer-based smart targeting and spatial trigger\u2013response drug-delivery systems for anticancer therapy. Biomedicines. 2024;12:187. https:\/\/doi.org\/10.3390\/biomedicines12010187.","journal-title":"Biomedicines."},{"key":"3522_CR122","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.actbio.2018.10.012","volume":"82","author":"X Zhu","year":"2018","unstructured":"Zhu X, Zhou H, Liu Y, Wen Y, Wei C, Yu Q, et al. Transferrin\/aptamer conjugated mesoporous ruthenium nanosystem for redox-controlled and targeted chemo-photodynamic therapy of glioma. Acta Biomater. 2018;82:143\u201357. https:\/\/doi.org\/10.1016\/j.actbio.2018.10.012.","journal-title":"Acta Biomater"},{"key":"3522_CR123","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3390\/pharmaceutics11070301","volume":"11","author":"K Kim","year":"2019","unstructured":"Kim K, Choi H, Choi ES, Park M-H, Ryu J-H. Hyaluronic acid-coated nanomedicine for targeted cancer therapy. Pharmaceutics. 2019;11:301. https:\/\/doi.org\/10.3390\/pharmaceutics11070301.","journal-title":"Pharmaceutics"},{"key":"3522_CR124","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1039\/C2NR32145A","volume":"5","author":"M Yu","year":"2012","unstructured":"Yu M, Jambhrunkar S, Thorn P, Chen J, Gu W, Yu C. Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells. Nanoscale. 2012;5:178\u201383. https:\/\/doi.org\/10.1039\/C2NR32145A.","journal-title":"Nanoscale"},{"key":"3522_CR125","doi-asserted-by":"publisher","first-page":"34158","DOI":"10.18632\/oncotarget.8926","volume":"7","author":"SL Hayward","year":"2016","unstructured":"Hayward SL, Wilson CL, Kidambi S. Hyaluronic acid-conjugated liposome nanoparticles for targeted delivery to CD44 overexpressing glioblastoma cells. Oncotarget. 2016;7:34158\u201371. https:\/\/doi.org\/10.18632\/oncotarget.8926.","journal-title":"Oncotarget."},{"key":"3522_CR126","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1021\/acsbiomaterials.8b00218","volume":"4","author":"L Palanikumar","year":"2018","unstructured":"Palanikumar L, Kim J, Oh JY, Choi H, Park M-H, Kim C, et al. Hyaluronic acid-modified polymeric gatekeepers on biodegradable mesoporous silica nanoparticles for targeted cancer therapy. ACS Biomater Sci Eng. 2018;4:1716\u201322. https:\/\/doi.org\/10.1021\/acsbiomaterials.8b00218.","journal-title":"ACS Biomater Sci Eng."},{"key":"3522_CR127","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.2147\/IJN.S213974","volume":"14","author":"Z Fang","year":"2019","unstructured":"Fang Z, Li X, Xu Z, Du F, Wang W, Shi R, et al. Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe3O4 nanoparticles for targeted drug delivery. Int J Nanomedicine. 2019;14:5785\u201397. https:\/\/doi.org\/10.2147\/IJN.S213974.","journal-title":"Int J Nanomedicine"},{"key":"3522_CR128","doi-asserted-by":"publisher","first-page":"e3481397","DOI":"10.1155\/2019\/3481397","volume":"2019","author":"S Park","year":"2019","unstructured":"Park S, Park H, Jeong S, Yi BG, Park K, Key J. Hyaluronic acid-conjugated mesoporous silica nanoparticles loaded with dual anticancer agents for chemophotodynamic cancer therapy. J Nanomater. 2019;2019:e3481397. https:\/\/doi.org\/10.1155\/2019\/3481397.","journal-title":"J Nanomater."},{"key":"3522_CR129","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/chem.201202038","volume":"19","author":"Z Chen","year":"2013","unstructured":"Chen Z, Li Z, Lin Y, Yin M, Ren J, Qu X. Bioresponsive hyaluronic acid-capped mesoporous silica nanoparticles for targeted drug delivery. Chemistry. 2013;19:1778\u201383. https:\/\/doi.org\/10.1002\/chem.201202038.","journal-title":"Chemistry"},{"key":"3522_CR130","doi-asserted-by":"publisher","first-page":"13262","DOI":"10.3390\/ijms241713262","volume":"24","author":"P Kawak","year":"2023","unstructured":"Kawak P, Sawaftah NMA, Pitt WG, Husseini GA. Transferrin-targeted liposomes in glioblastoma therapy: a review. Int J Mol Sci. 2023;24:13262. https:\/\/doi.org\/10.3390\/ijms241713262.","journal-title":"Int J Mol Sci."},{"key":"3522_CR131","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1039\/d2bm02152h","volume":"11","author":"J Li","year":"2023","unstructured":"Li J, Zhang Z, Zhang B, Yan X, Fan K. Transferrin receptor 1 targeted nanomedicine for brain tumor therapy. Biomater Sci. 2023;11:3394\u2013413. https:\/\/doi.org\/10.1039\/d2bm02152h.","journal-title":"Biomater Sci"},{"key":"3522_CR132","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3390\/pharmaceutics14020279","volume":"14","author":"MJ Ramalho","year":"2022","unstructured":"Ramalho MJ, Loureiro JA, Coelho MAN, Pereira MC. Transferrin receptor-targeted nanocarriers: overcoming barriers to treat glioblastoma. Pharmaceutics. 2022;14:279. https:\/\/doi.org\/10.3390\/pharmaceutics14020279.","journal-title":"Pharmaceutics"},{"key":"3522_CR133","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.colsurfb.2017.01.010","volume":"152","author":"X Chen","year":"2017","unstructured":"Chen X, Sun H, Hu J, Han X, Liu H, Hu Y. Transferrin gated mesoporous silica nanoparticles for redox-responsive and targeted drug delivery. Colloids Surf B Biointerfaces. 2017;152:77\u201384. https:\/\/doi.org\/10.1016\/j.colsurfb.2017.01.010.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3522_CR134","doi-asserted-by":"publisher","unstructured":"Heggannavar GB, Hiremath CG, Achari DD, Pangarkar VG, Kariduraganavar MY. Development of doxorubicin-loaded magnetic Silica\u2013Pluronic F-127 nanocarriers conjugated with transferrin for treating glioblastoma across the blood\u2013brain barrier using an in vitro model. ACS Omega [Internet]. American Chemical Society; 2018 [cited 2025 Mar 13]; https:\/\/doi.org\/10.1021\/acsomega.8b00152","DOI":"10.1021\/acsomega.8b00152"},{"key":"3522_CR135","doi-asserted-by":"publisher","unstructured":"Bansal KK, Mishra DK, Rosling A, Rosenholm JM. Therapeutic Potential of Polymer-Coated Mesoporous Silica Nanoparticles. Applied Sciences. Multidisciplinary Digital Publishing Institute; 2020;10:289. https:\/\/doi.org\/10.3390\/app10010289","DOI":"10.3390\/app10010289"},{"key":"3522_CR136","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.3390\/polym13234114","volume":"13","author":"B Rabha","year":"2021","unstructured":"Rabha B, Bharadwaj KK, Pati S, Choudhury BK, Sarkar T, Kari ZA, Edinur HA, Baishya D, Atanase LI. Development of polymer-based nanoformulations for glioblastoma brain cancer therapy and diagnosis: an update. Polymers. 2021;13:4114. https:\/\/doi.org\/10.3390\/polym13234114.","journal-title":"Polymers"},{"key":"3522_CR137","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/978-3-030-40513-7_80","volume-title":"Handbook of polymer and ceramic nanotechnology","author":"MA Subhan","year":"2021","unstructured":"Subhan MA, Torchilin VP. Biocompatible polymeric nanoparticles as promising candidates for drug delivery in cancer treatment. In: Hussain CM, Thomas S, editors. Handbook of polymer and ceramic nanotechnology. Cham: Springer International Publishing; 2021. p. 855\u201372. https:\/\/doi.org\/10.1007\/978-3-030-40513-7_80."},{"key":"3522_CR138","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1016\/j.actbio.2012.06.003","volume":"8","author":"S Bhattacharyya","year":"2012","unstructured":"Bhattacharyya S, Wang H, Ducheyne P. Polymer-coated mesoporous silica nanoparticles for the controlled release of macromolecules. Acta Biomater. 2012;8:3429\u201335. https:\/\/doi.org\/10.1016\/j.actbio.2012.06.003.","journal-title":"Acta Biomater"},{"key":"3522_CR139","doi-asserted-by":"publisher","unstructured":"Santhanakrishnan KR, Koilpillai J, Narayanasamy D. PEGylation in pharmaceutical development: current status and emerging trends in macromolecular and immunotherapeutic drugs. Cureus. 16:e66669. https:\/\/doi.org\/10.7759\/cureus.66669","DOI":"10.7759\/cureus.66669"},{"key":"3522_CR140","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.apsb.2018.01.007","volume":"8","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Quan G, Wu Q, Zhang X, Niu B, Wu B, et al. Mesoporous silica nanoparticles for drug and gene delivery. Acta Pharmaceutica Sinica B. 2018;8:165\u201377. https:\/\/doi.org\/10.1016\/j.apsb.2018.01.007.","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"3522_CR141","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/03639045.2022.2101062","volume":"48","author":"E Sanchez Armengol","year":"2022","unstructured":"Sanchez Armengol E, Unterweger A, Laffleur F. PEGylated drug delivery systems in the pharmaceutical field: past, present and future perspective. Drug Devel Indust Pharm. 2022;48:129\u201339. https:\/\/doi.org\/10.1080\/03639045.2022.2101062.","journal-title":"Drug Devel Indust Pharm."},{"key":"3522_CR142","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s13346-013-0176-5","volume":"3","author":"JJF Verhoef","year":"2013","unstructured":"Verhoef JJF, Anchordoquy TJ. Questioning the use of PEGylation for drug delivery. Drug Deliv Transl Res. 2013;3:499\u2013503.","journal-title":"Drug Deliv Transl Res"},{"key":"3522_CR143","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1517\/14728214.2015.1113254","volume":"20","author":"M Swierczewska","year":"2015","unstructured":"Swierczewska M, Lee KC, Lee S. What is the future of PEGylated therapies? Expert Opin Emerg Drugs. 2015;20:531\u20136. https:\/\/doi.org\/10.1517\/14728214.2015.1113254.","journal-title":"Expert Opin Emerg Drugs"},{"key":"3522_CR144","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","volume":"10","author":"FM Veronese","year":"2005","unstructured":"Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discovery Today. 2005;10:1451\u20138. https:\/\/doi.org\/10.1016\/S1359-6446(05)03575-0.","journal-title":"Drug Discovery Today"},{"key":"3522_CR145","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.colsurfb.2016.10.018","volume":"149","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, Zhao H, Li D, Liu L, Du S. A surface-grafted ligand functionalization strategy for coordinate binding of doxorubicin at surface of PEGylated mesoporous silica nanoparticles: toward pH-responsive drug delivery. Colloids Surf, B. 2017;149:138\u201345. https:\/\/doi.org\/10.1016\/j.colsurfb.2016.10.018.","journal-title":"Colloids Surf, B"},{"key":"3522_CR146","doi-asserted-by":"publisher","unstructured":"Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres M del P, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018;16:1\u201333. https:\/\/doi.org\/10.1186\/s12951-018-0392-8","DOI":"10.1186\/s12951-018-0392-8"},{"key":"3522_CR147","doi-asserted-by":"publisher","unstructured":"Lara-Velazquez M, Alkharboosh R, Norton ES, Ramirez-Loera C, Freeman WD, Guerrero-Cazares H, et al. Chitosan-based non-viral gene and drug delivery systems for brain cancer. Front Neurol [Internet]. Frontiers; 2020 [cited 2025 Jan 7];11. https:\/\/doi.org\/10.3389\/fneur.2020.00740","DOI":"10.3389\/fneur.2020.00740"},{"key":"3522_CR148","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1016\/j.ijbiomac.2021.06.004","volume":"183","author":"T Liao","year":"2021","unstructured":"Liao T, Liu C, Ren J, Chen H, Kuang Y, Jiang B, et al. A chitosan\/mesoporous silica nanoparticle-based anticancer drug delivery system with a \u201ctumor-triggered targeting\u201d property. Int J Biol Macromol. 2021;183:2017\u201329. https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.06.004.","journal-title":"Int J Biol Macromol"},{"key":"3522_CR149","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10847-017-0741-5","volume":"89","author":"P Deveci","year":"2017","unstructured":"Deveci P, Taner B, Albayat\u0131 SHM. Mesoporous silica and chitosan based pH-sensitive smart nanoparticles for tumor targeted drug delivery. J Incl Phenom Macrocycl Chem. 2017;89:15\u201327. https:\/\/doi.org\/10.1007\/s10847-017-0741-5.","journal-title":"J Incl Phenom Macrocycl Chem."},{"key":"3522_CR150","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3390\/molecules26092490","volume":"26","author":"Q Li","year":"2021","unstructured":"Li Q, Wang W, Hu G, Cui X, Sun D, Jin Z, et al. Evaluation of chitosan derivatives modified mesoporous silica nanoparticles as delivery carrier. Molecules. 2021;26:2490. https:\/\/doi.org\/10.3390\/molecules26092490.","journal-title":"Molecules."},{"key":"3522_CR151","doi-asserted-by":"publisher","first-page":"105072","DOI":"10.1016\/j.reactfunctpolym.2021.105072","volume":"169","author":"Z Lin","year":"2021","unstructured":"Lin Z, Gong C, Tang L, Cao B, Kong F, Wang Z, et al. Study on preparation and in vitro anti-tumor activity of chitosan-modified mesoporous silica hybrids by GPTMS cross-linking agent. React Funct Polym. 2021;169:105072. https:\/\/doi.org\/10.1016\/j.reactfunctpolym.2021.105072.","journal-title":"React Funct Polym"},{"key":"3522_CR152","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.2147\/IJN.S206899","volume":"14","author":"SA Shahein","year":"2019","unstructured":"Shahein SA, Aboul-Enein AM, Higazy IM, Abou-Elella F, Lojkowski W, Ahmed ER, et al. Targeted anticancer potential against glioma cells of thymoquinone delivered by mesoporous silica core-shell nanoformulations with pH-dependent release. Int J Nanomed. 2019;14:5503\u201326. https:\/\/doi.org\/10.2147\/IJN.S206899.","journal-title":"Int J Nanomed."},{"key":"3522_CR153","doi-asserted-by":"publisher","DOI":"10.1039\/c6ra17290c","author":"P Kesharwani","year":"2016","unstructured":"Kesharwani P, Jain A, Jain A, Jain A, Garg NK, Tekade R, et al. Cationic bovine serum albumin (CBA) conjugated poly lactic-co-glycolic acid (PLGA) nanoparticles for extended delivery of methotrexate into brain tumors. RSC Adv. 2016. https:\/\/doi.org\/10.1039\/c6ra17290c.","journal-title":"RSC Adv"},{"key":"3522_CR154","unstructured":"Borah A, Palaninathan V, Girija A, Balasubramanian S, Rochani AK, Maekawa T, et al. Poly-lactic-co-glycolic acid Nanoformulation of Small Molecule Antagonist GANT61 for Cancer Annihilation by Modulating Hedgehog Pathway [Internet]. 2017 [cited 2025 Jan 8]. https:\/\/www.semanticscholar.org\/paper\/Poly-lactic-co-glycolic-acid-Nanoformulation-of-for-Borah-Palaninathan\/df67aa689267d58b28630f9d7e5252516c014d9d. Accessed 8 Jan 2025"},{"key":"3522_CR155","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/ijms17091440","volume":"17","author":"PI Siafaka","year":"2016","unstructured":"Siafaka PI, \u00dcst\u00fcnda\u011fOkur N, Karavas E, Bikiaris DN. Surface modified multifunctional and stimuli responsive nanoparticles for drug targeting: current status and uses. Int J Mol Sci. 2016;17:1440. https:\/\/doi.org\/10.3390\/ijms17091440.","journal-title":"Int J Mol Sci."},{"key":"3522_CR156","doi-asserted-by":"publisher","first-page":"14191","DOI":"10.1021\/acsanm.3c02122","volume":"6","author":"MJ Ramalho","year":"2023","unstructured":"Ramalho MJ, Torres ID, Loureiro JA, Lima J, Pereira MC. Transferrin-Conjugated PLGA Nanoparticles for Co-Delivery of Temozolomide and Bortezomib to Glioblastoma Cells. ACS Appl Nano Mater. 2023;6:14191\u2013203. https:\/\/doi.org\/10.1021\/acsanm.3c02122.","journal-title":"ACS Appl Nano Mater"},{"key":"3522_CR157","doi-asserted-by":"publisher","first-page":"101157","DOI":"10.1016\/j.jddst.2019.101157","volume":"53","author":"GB Heggannavar","year":"2019","unstructured":"Heggannavar GB, Vijeth S, Kariduraganavar MY. Development of dual drug loaded PLGA based mesoporous silica nanoparticles and their conjugation with Angiopep-2 to treat glioma. J Drug Del Sci Technol. 2019;53:101157. https:\/\/doi.org\/10.1016\/j.jddst.2019.101157.","journal-title":"J Drug Del Sci Technol"},{"key":"3522_CR158","doi-asserted-by":"publisher","unstructured":"Cui Y, Xu Q, Chow PK-H, Wang D, Wang C-H. Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. Biomaterials. 2013;34:8511\u201320. https:\/\/doi.org\/10.1016\/j.biomaterials.2013.07.075","DOI":"10.1016\/j.biomaterials.2013.07.075"},{"key":"3522_CR159","doi-asserted-by":"publisher","first-page":"36194","DOI":"10.1038\/s41598-025-20012-x","volume":"15","author":"\u015e \u015eahin","year":"2025","unstructured":"\u015eahin \u015e, Kaya-Tilki E, Baysal M, \u00d6zt\u00fcrk AA. Preparation and evaluation of temozolomide loaded PLGA nanoparticles for the treatment of glioblastoma multiforme. Sci Rep. 2025;15:36194. https:\/\/doi.org\/10.1038\/s41598-025-20012-x.","journal-title":"Sci Rep."},{"key":"3522_CR160","doi-asserted-by":"publisher","first-page":"6250","DOI":"10.1021\/acs.biomac.4c00722","volume":"25","author":"M Ismail","year":"2024","unstructured":"Ismail M, Wang Y, Li Y, Liu J, Zheng M, Zou Y. Stimuli-Responsive Polymeric Nanocarriers Accelerate On-Demand Drug Release to Combat Glioblastoma. Biomacromol. 2024;25:6250\u201382. https:\/\/doi.org\/10.1021\/acs.biomac.4c00722.","journal-title":"Biomacromol"},{"key":"3522_CR161","doi-asserted-by":"publisher","unstructured":"Mainuddin, Tomar D, Jindal A, Anshika, Khan J, Kumar A. Stimuli-responsive mesoporous silica nanoparticles for brain tumor theranostics and drug targeting. Drug Devel Indust Pharm. 2026;0:1\u201322. https:\/\/doi.org\/10.1080\/03639045.2026.2624601","DOI":"10.1080\/03639045.2026.2624601"},{"key":"3522_CR162","doi-asserted-by":"publisher","unstructured":"Khan J, Jindal A, Kumar A, Mainuddin, Sharma N. Tuning stimuli-triggered mesoporous silica nanoparticles in novel way of brain cancer therapy. BioNanoSci. 2025;15:1\u201316. https:\/\/doi.org\/10.1007\/s12668-024-01611-w","DOI":"10.1007\/s12668-024-01611-w"},{"key":"3522_CR163","doi-asserted-by":"publisher","DOI":"10.1002\/adbi.201800020","volume":"2","author":"A Rahikkala","year":"2018","unstructured":"Rahikkala A, Pereira SAP, Figueiredo P, Passos MLC, Ara\u00fajo ARTS, Saraiva MLMFS, et al. Mesoporous silica nanoparticles for targeted and stimuli-responsive delivery of chemotherapeutics: a review. Adv Biosyst. 2018;2:1800020. https:\/\/doi.org\/10.1002\/adbi.201800020.","journal-title":"Adv Biosyst"},{"key":"3522_CR164","doi-asserted-by":"publisher","first-page":"7747","DOI":"10.7150\/thno.112492","volume":"15","author":"J Hao","year":"2025","unstructured":"Hao J, Li Y, Huang L, Qi N, Sun Y, He C, et al. Smart Nanoarchitectures for Precision RNA Delivery: Harnessing Endogenous and Exogenous Stimuli in Cancer Treatment. Theranostics Ivyspring International Publisher. 2025;15:7747\u201378. https:\/\/doi.org\/10.7150\/thno.112492.","journal-title":"Theranostics Ivyspring International Publisher"},{"key":"3522_CR165","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3390\/nano5041906","volume":"5","author":"M Mart\u00ednez-Carmona","year":"2015","unstructured":"Mart\u00ednez-Carmona M, Colilla M, Vallet-Reg\u00ed M. Smart mesoporous nanomaterials for antitumor therapy. Nanomaterials. 2015;5:1906\u201337. https:\/\/doi.org\/10.3390\/nano5041906.","journal-title":"Nanomaterials"},{"key":"3522_CR166","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1021\/acs.molpharmaceut.2c00755","volume":"20","author":"N Shadmani","year":"2023","unstructured":"Shadmani N, Makvandi P, Parsa M, Azadi A, Nedaei K, Mozafari N, et al. Enhancing methotrexate delivery in the brain by mesoporous silica nanoparticles functionalized with cell-penetrating peptide using in vivo and ex vivo monitoring. Mol Pharm. 2023;20:1531\u201348. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00755.","journal-title":"Mol Pharm"},{"key":"3522_CR167","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1039\/D1TB02540F","volume":"10","author":"J Liu","year":"2022","unstructured":"Liu J, Hu X, Jin S, Liang X-J, Ma X. Enhanced anti-tumor activity of a drug through pH-triggered release and dual targeting by calcium phosphate-covered mesoporous silica vehicles. J Mater Chem B Royal Soc Chem. 2022;10:384\u201395. https:\/\/doi.org\/10.1039\/D1TB02540F.","journal-title":"J Mater Chem B Royal Soc Chem."},{"key":"3522_CR168","doi-asserted-by":"publisher","first-page":"111818","DOI":"10.1016\/j.eurpolymj.2023.111818","volume":"185","author":"N-H Truong-Thi","year":"2023","unstructured":"Truong-Thi N-H, Nguyen NH, Nguyen DTD, Tang TN, Nguyen TH, Nguyen DH. pH-responsive delivery of Platinum-based drugs through the surface modification of heparin on mesoporous silica nanoparticles. Eur Polymer J. 2023;185:111818. https:\/\/doi.org\/10.1016\/j.eurpolymj.2023.111818.","journal-title":"Eur Polymer J"},{"key":"3522_CR169","doi-asserted-by":"publisher","first-page":"112715","DOI":"10.1016\/j.matdes.2024.112715","volume":"238","author":"Y Liu","year":"2024","unstructured":"Liu Y, Yu S, Jiang X, Wu Q, Shen W, Zou Z, et al. Functional paclitaxel-manganese-doped mesoporous silica nanoparticles for orthotopic brain glioma targeted therapy. Mater Des. 2024;238:112715. https:\/\/doi.org\/10.1016\/j.matdes.2024.112715.","journal-title":"Mater Des"},{"key":"3522_CR170","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.msec.2018.12.138","volume":"98","author":"A Sodagar Taleghani","year":"2019","unstructured":"Sodagar Taleghani A, Ebrahimnejad P, Heidarinasab A, Akbarzadeh A. Sugar-conjugated dendritic mesoporous silica nanoparticles as pH-responsive nanocarriers for tumor targeting and controlled release of deferasirox. Mater Sci Eng C. 2019;98:358\u201368. https:\/\/doi.org\/10.1016\/j.msec.2018.12.138.","journal-title":"Mater Sci Eng C"},{"key":"3522_CR171","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3390\/pharmaceutics15030795","volume":"15","author":"K Thirupathi","year":"2023","unstructured":"Thirupathi K, Santhamoorthy M, Radhakrishnan S, Ulagesan S, Nam T-J, Phan TTV, et al. Thermosensitive polymer-modified mesoporous silica for pH and temperature-responsive drug delivery. Pharmaceutics. 2023;15:795. https:\/\/doi.org\/10.3390\/pharmaceutics15030795.","journal-title":"Pharmaceutics."},{"key":"3522_CR172","doi-asserted-by":"publisher","unstructured":"Chen M, Hu J, Wang L, Li Y, Zhu C, Chen C, et al. Targeted and redox-responsive drug delivery systems based on carbonic anhydrase IX-decorated mesoporous silica nanoparticles for cancer therapy. Sci Rep. Nature Publishing Group; 2020;10:14447. https:\/\/doi.org\/10.1038\/s41598-020-71071-1","DOI":"10.1038\/s41598-020-71071-1"},{"key":"3522_CR173","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.1016\/j.ceramint.2020.10.022","volume":"47","author":"Y He","year":"2021","unstructured":"He Y, Shao L, Hu Y, Zhao F, Tan S, He D, et al. Redox and pH dual-responsive biodegradable mesoporous silica nanoparticle as a potential drug carrier for synergistic cancer therapy. Ceram Int. 2021;47:4572\u20138. https:\/\/doi.org\/10.1016\/j.ceramint.2020.10.022.","journal-title":"Ceram Int"},{"key":"3522_CR174","doi-asserted-by":"publisher","first-page":"101510","DOI":"10.1016\/j.jddst.2020.101510","volume":"57","author":"F Bahrami","year":"2020","unstructured":"Bahrami F, Abdekhodaie MJ, Behroozi F, Mehrvar M. Nano mesoporous silica for cancer treatment: ROS-responsive and redox-responsive carriers. J Drug Del Sci Technol. 2020;57:101510. https:\/\/doi.org\/10.1016\/j.jddst.2020.101510.","journal-title":"J Drug Del Sci Technol"},{"key":"3522_CR175","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/17425247.2021.1828339","volume":"18","author":"J Majumder","year":"2021","unstructured":"Majumder J, Minko T. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opinion Drug Deliv. 2021;18:205\u201327. https:\/\/doi.org\/10.1080\/17425247.2021.1828339.","journal-title":"Expert Opinion Drug Deliv."},{"key":"3522_CR176","doi-asserted-by":"publisher","unstructured":"Moghaddas J, Ramezanian S, Roghani-Mamaqani H, Rezamand A. Dual pH- and temperature-responsive Poly(Dimethylaminoethyl Methacrylate)-Coated Mesoporous Silica Nanoparticles as a Smart Drug Delivery System [Internet]. Rochester, NY: Social Science Research Network; 2023 [cited 2025 Jan 9]. https:\/\/doi.org\/10.2139\/ssrn.4432639","DOI":"10.2139\/ssrn.4432639"},{"key":"3522_CR177","doi-asserted-by":"publisher","first-page":"103197","DOI":"10.1016\/j.jddst.2022.103197","volume":"70","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Zhang M, Wei S, Wang B, He J, Qiu X. Temperature-responsive P(NIPAM-co-NHMA)-grafted organic-inorganic hybrid hollow mesoporous silica nanoparticles for controlled drug delivery. J Drug Deliv Sci Technol. 2022;70:103197. https:\/\/doi.org\/10.1016\/j.jddst.2022.103197.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3522_CR178","doi-asserted-by":"publisher","first-page":"126719","DOI":"10.1016\/j.colsurfa.2021.126719","volume":"623","author":"S Porrang","year":"2021","unstructured":"Porrang S, Rahemi N, Davaran S, Mahdavi M, Hassanzadeh B. Synthesis of temperature\/pH dual-responsive mesoporous silica nanoparticles by surface modification and radical polymerization for anti-cancer drug delivery. Colloids Surf A. 2021;623:126719. https:\/\/doi.org\/10.1016\/j.colsurfa.2021.126719.","journal-title":"Colloids Surf A"},{"key":"3522_CR179","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3390\/pharmaceutics12060527","volume":"12","author":"S Barui","year":"2020","unstructured":"Barui S, Cauda V. Multimodal decorations of mesoporous silica nanoparticles for improved cancer therapy. Pharmaceutics. 2020;12:527. https:\/\/doi.org\/10.3390\/pharmaceutics12060527.","journal-title":"Pharmaceutics."},{"key":"3522_CR180","doi-asserted-by":"publisher","unstructured":"Saravanakumar G, Kim WJ. Light-Induced Reactive-Oxygen-Species- (ROS-) Mediated activation of self-assembled nanoplatforms for on-demand drug delivery. Sakurai K, Ilies MA, editors. American Chemical Society; 2019;1309:253\u201385. https:\/\/doi.org\/10.1021\/bk-2019-1309.ch011","DOI":"10.1021\/bk-2019-1309.ch011"},{"key":"3522_CR181","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1007\/s10853-019-03325-x","volume":"54","author":"M Wang","year":"2019","unstructured":"Wang M, Wang T, Wang D, Jiang W, Fu J. Acid and light stimuli-responsive mesoporous silica nanoparticles for controlled release. J Mater Sci. 2019;54:6199\u2013211. https:\/\/doi.org\/10.1007\/s10853-019-03325-x.","journal-title":"J Mater Sci"},{"key":"3522_CR182","doi-asserted-by":"publisher","unstructured":"Tian Y, Kong Y, Li X, Wu J, Ko AC-T, Xing M. Light- and pH-activated intracellular drug release from polymeric mesoporous silica nanoparticles. Colloids Surf B Biointer. 2015;134:147\u201355. https:\/\/doi.org\/10.1016\/j.colsurfb.2015.04.069","DOI":"10.1016\/j.colsurfb.2015.04.069"},{"key":"3522_CR183","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1021\/acsbiomaterials.0c01347","volume":"6","author":"FSC Rodrigues","year":"2020","unstructured":"Rodrigues FSC, Campos A, Martins J, Ambr\u00f3sio AF, Campos EJ. Emerging trends in nanomedicine for improving ocular drug delivery: light-responsive nanoparticles, mesoporous silica nanoparticles, and contact lenses. ACS Biomater Sci Eng. 2020;6:6587\u201397. https:\/\/doi.org\/10.1021\/acsbiomaterials.0c01347.","journal-title":"ACS Biomater Sci Eng."},{"key":"3522_CR184","doi-asserted-by":"publisher","unstructured":"Chen C, Tang W, Jiang D, Yang G, Wang X-L, Zhou L, et al. Hyaluronic acid conjugated polydopamine functionalized mesoporous silica nanoparticles for synergistic targeted chemo-photothermal therapy. Nanoscale. 2019;11. https:\/\/doi.org\/10.1039\/C9NR01385G","DOI":"10.1039\/C9NR01385G"},{"key":"3522_CR185","doi-asserted-by":"publisher","first-page":"6999","DOI":"10.2147\/IJN.S466268","volume":"19","author":"M Li","year":"2024","unstructured":"Li M, Zhang X, Zhou Y, Chu Y, Shen J, Cai Y, et al. Near infrared-activatable biomimetic nanoplatform for tumor-specific drug release, penetration and chemo-photothermal synergistic therapy of orthotopic glioblastoma. Int J Nanomedicine. 2024;19:6999\u20137014. https:\/\/doi.org\/10.2147\/IJN.S466268.","journal-title":"Int J Nanomedicine"},{"key":"3522_CR186","unstructured":"JERMY BR, Ravinayagam V. Method for treating breast cancer with a chemotherapeutic drug carrier [Internet]. 2023 [cited 2024 Dec 17]. https:\/\/patents.google.com\/patent\/US11701438B2\/en?q=(mesoporous+silica+nanoparticles+brain+cancer)&oq=mesoporous+silica+nanoparticles+for+brain+cancer. Accessed 17 Dec 2024"},{"key":"3522_CR187","unstructured":"Liong M, Lu J, Tamanoi F, Zink JI, Nel AE. Mesoporous silica nanoparticles for biomedical applications [Internet]. 2018 [cited 2024 Dec 19]. https:\/\/patents.google.com\/patent\/US20180344654A1\/en?q=~patent%2fUS11701438B2. Accessed 19 Dec 2024"},{"key":"3522_CR188","unstructured":"JERMY BR, Ravinayagam V. Equilibrium adsorption method for making a silica nanocarrier spion composition [Internet]. 2024 [cited 2024 Dec 19]. https:\/\/patents.google.com\/patent\/US11865193B2\/en?q=(~patent%2fUS11701438B2). Accessed 19 Dec 2024"},{"key":"3522_CR189","unstructured":"KR102408525B1 - Mesoporous Silica Nanoparticles with Lipid Bilayer Coating for Cargo Delivery - Google Patents [Internet]. [cited 2024 Dec 19]. https:\/\/patents.google.com\/patent\/KR102408525B1\/en?oq=KR102408525B1. Accessed 19 Dec 2024"},{"key":"3522_CR190","unstructured":"\u674e\u6842\u82f1, \u90ed\u5cf0, \u90ed\u78ca, \u8d56\u5409\u59ae, \u9648\u5fc3\u4eea. \u4e00\u79cd\u6838\u58f3\u7ed3\u6784\u591a\u529f\u80fd\u4ecb\u5b54\u7845\u836f\u7269\u8f7d\u4f53\u7684\u5236\u5907\u65b9\u6cd5 [Internet]. 2022 [cited 2024 Dec 19]. https:\/\/patents.google.com\/patent\/CN110151729B\/en?oq=CN110151729B. Accessed 19 Dec 2024"},{"key":"3522_CR191","unstructured":"Nanospectra Biosciences, Inc. A pilot study of AuroLase(tm) Therapy in Patients With Refractory and/or recurrent tumors of the head and neck [Internet]. clinicaltrials.gov; 2016 Dec. Report No.: NCT00848042. https:\/\/clinicaltrials.gov\/study\/NCT00848042. Accessed 19 Dec 2024"},{"key":"3522_CR192","unstructured":"Memorial Sloan Kettering Cancer Center. PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study [Internet]. clinicaltrials.gov; 2023 Dec. Report No.: NCT01266096. https:\/\/clinicaltrials.gov\/study\/NCT01266096. Accessed 19 Dec 2024"},{"key":"3522_CR193","unstructured":"Memorial Sloan Kettering Cancer Center. targeted silica nanoparticles for real-time image-guided intraoperative mapping of nodal metastases [Internet]. clinicaltrials.gov; 2024 May. Report No.: NCT02106598. https:\/\/clinicaltrials.gov\/study\/NCT02106598. Accessed 19 Dec 2024"},{"key":"3522_CR194","unstructured":"Memorial Sloan Kettering Cancer Center. Imaging of Patients With Malignant Brain Tumors Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers: A Phase 1 Microdosing Study [Internet]. clinicaltrials.gov; 2024 Apr. Report No.: NCT03465618. https:\/\/clinicaltrials.gov\/study\/NCT03465618. Accessed 19 Dec 2024"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03522-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03522-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03522-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:36:02Z","timestamp":1789432562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03522-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":194,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3522"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03522-3","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors state that the manuscript contains no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"298"}}